W7L Warpaint London

Hardman & Co Research: Diurnal Group (DNL): First commercial revenues

Hardman & Co Research
Hardman & Co Research: Diurnal Group (DNL): First commercial revenues

04-Oct-2018 / 17:10 GMT/BST

Hardman & Co: First commercial revenues

Diurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products target rare conditions where medical needs are currently unmet, with the aim of building a long-term 'Adrenal Franchise'. Following approval from the European Commission, Alkindi is being launched in key EU markets through DNL's own commercial infrastructure, starting with Germany and now launched in the UK. Additional territories will follow during 2018 and 2019. Meanwhile, the company is pushing forward with Alkindi and Chronocort clinical trials in the US. Cash at the end of the period was £17.3m.

Please click here for the full report:

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

Follow us on Twitter @HardmanandCo		 Contacts:

Dr Martin Hall
Dr Dorothea Hill
Dr Gregoire Pave

2



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

730409  04-Oct-2018 

fncls.ssp?fn=show_t_gif&application_id=730409&application_name=news&site_id=research_pool
EN
04/10/2018

Underlying

W7LWarpaint London

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Warpaint London

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson
STX Shield Therapeu...
W7L WARPAINT LONDON ... (+10)

Hybridan Small Cap Feast: 9 February 2026

* A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: Versarien (VRS.L) left AIM. What’s baking in the oven? Market Movers:*** 14 January: GlobalData (DATA.L), the data, insight, a...

STX SHIELD THERAPEUTICS
W7L WARPAINT LONDON
PXC PHOENIX COPPER
POW POWER METAL RESOURCES
AREC ARECOR THERAPEUTICS
DEVO DEVOLVER DIGITAL INC
AURR AURRIGO INTERNATIONAL PLC
PALM PANTHER METALS PLC
PWR POWER PROBE PLC
NEWS PATHOS COMMUNICATIONS LIMITED
02/09/26 February 9, 2026 1 EN
 PRESS RELEASE
Free
W7L WARPAINT LONDON

Form 8.3 - Warpaint London PLC

Apex Fundrock Limited (MISL) Form 8.3 - Warpaint London PLC 10-Feb-2025 / 11:50 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and benefi...

February 10, 2025 1 EN
 PRESS RELEASE
Free
W7L WARPAINT LONDON

Form 8.3 - Warpaint London PLC

Apex Fundrock Limited (MISL) Form 8.3 - Warpaint London PLC 07-Feb-2025 / 09:53 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and benefi...

February 7, 2025 1 EN
 PRESS RELEASE
Free
W7L WARPAINT LONDON

Form 8.3 - Warpaint London PLC

Apex Fundrock Limited (MISL) Form 8.3 - Warpaint London PLC 30-Jan-2025 / 09:43 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and benefi...

January 30, 2025 1 EN
 PRESS RELEASE
Free
W7L WARPAINT LONDON

Form 8.3 - Warpaint London PLC

Apex Fundrock Limited (MISL) Form 8.3 - Warpaint London PLC 09-Jan-2025 / 13:26 GMT/BST FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)   1. KEY INFORMATION   (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient.  For a trust, the trustee(s), settlor and benefi...

January 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch